<DOC>
	<DOCNO>NCT01445561</DOCNO>
	<brief_summary>Background : - Interleukin-2 drug help stimulate body response inflammation . High dose interleukin-2 use treat different type cancer immune system disorder . However , cause frequent often serious side effect dose currently use treatment . Very low dose interleukin-2 ( 700 fold less regular dose ) previously test cancer patient stem cell transplant recipient . The study observe important immune change minimal side effect patient . Researchers want test healthy immune system 's response low dos interleukin-2 good understand drug work . Objectives : - To study effect low dos interleukin-2 healthy volunteer . Eligibility : - Healthy volunteer least 18 year age . Design : - Participants screen medical history physical exam . They also blood urine sample . - Participants receive one two possible low dos interleukin-2 every day 5 day . - Blood sample take twice first dose , 1 day first dose , next three dos . Followup blood sample take Days 7 , 14 , 28 first dose .</brief_summary>
	<brief_title>Ultra Low Dose Interleukin-2 Healthy Volunteers</brief_title>
	<detailed_description>Interleukin 2 ( IL-2 , aldesleukin ) discover T cell growth factor 30 year ago . IL-2 first human cytokine use therapeutically . IL-2 induces antigen specific T cell , two important lymphocyte subset : regulatory T cell ( T-regs ) natural killer cell ( NK ) cell . T-regs critical role self-tolerance pathogenesis autoimmune disease graft versus host disease ( GVHD ) , extensively study solid tumor , hematologic malignancy , viral hepatitis , HIV infection . NK cell unique role bridge innate adaptive immunity . NK cell facilitate hematopoietic stem cell ( HSC ) engraftment reduce GVHD increase graft-versus-leukemia ( GVL ) effect . NK cell important role pathogenesis malignancy , autoimmune disease AIDS . Conventional dose IL-2 treatment promote marked expansion regulatory T cell , NK cell associate significant side effect . However , much low dose interleukin-2 ( 0.5- 1MIU/m2/day ) lack significant side effect , also induce expansion T regs NK cell . These observation suggest ultra low dose IL-2 would safe appropriate give hematopoietic stem cell donor . The quality transplant would improve high dose T-regs would reduce risk GVHD high NK cell would augment GVL effect . The aim study evaluate safety tolerability ultra low dose IL-2 healthy volunteer preferential expansion T-regs NK cell view extend ultra low dose IL-2 administration stem cell donor . We anticipate study provide valuable information biology IL-2 human immunome applicable various human disease condition , include cancer , immunodeficiency disease , autoimmune disease , hematopoietic stem cell transplantation . The propose IL-2 dose 2-3 log low manufacturer recommend dose . We therefore expect dose use protocol well tolerate . Nevertheless , little information tolerability safety IL-2 ultra low dos , structure study safety protocol stop rule unacceptable side effect . This important hope use safety data generate justify future protocol give ultra low dose IL-2 stem cell donor .</detailed_description>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>INCLUSION CRITERIA : Healthy volunteer confirm brief history physical examination blood work CHI screen protocol Males females age 18 year old EXCLUSION CRITERIA : History inflammatory autoimmune disease History inflammatory autoimmune disease first degree relative History malignancy Recipients hematopoietic stem cell transplant solid organ transplant History seizure Positive HIV , hepatitis B surface antigen hepatitis C antibody History clinical sign cardiac disease include coronary artery disease , cardiac arrhythmia , congestive heart failure History clinical sign pulmonary disease include obstructive lung disease asthma Active infection require systemic antibiotic therapy antiviral therapy History systemic fungal mycobacterial infection Use immune modifying medication , i.e . non steroidal antiinflammatory drug ( aspirin , ibuprofen , naproxen , celecoxib , ketrolac ) , steroid ( prednisone , dexamethasone , hydrocortisone ) , chemotherapy ( cisplatin , dacarbazine , interferon alpha , tamoxifen ) Persons alcoholic abuser illicit drug Female subject may pregnant lactate Psychiatric diagnosis symptom , include hypomania , bipolar disorder , major depression , dysthymia Abnormal marginal peripheral blood count opinion PI cause Hemoglobin Hematocrit level drop result participation study Liver function test normal laboratory reference range Renal function test normal laboratory reference range Contraindication interleukin2 ( i.e . hypersensitivity IL 2 product , active coronary artery disease , patient organ allograft ) Recent recipient type vaccination ( i.e . rotavirus vaccine , BCG , influenza virus vaccine , rubella virus vaccine , mumps virus vaccine , measles vaccine , poliovirus vaccine , smallpox vaccine , typhoid vaccine , varicella virus vaccine , yellow fever vaccine ) 4 week precede active study participation Body mass index great 35 Inability comprehend investigational nature study provide inform consent Diabetes mellitus fast blood glucose &gt; 100 mg/dL . Any drug supplement interfere blood clot Vit.E , NSAIDS , Warfarin ( Coumadin ) , ticlopidine ( Ticlid ) , clopidogrel ( Plavix ) Use iodinate contrast medium 4 week precede active study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 18, 2016</verification_date>
	<keyword>Interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Regulatory T Cells ( T regs )</keyword>
	<keyword>Natural Killer Cells ( NK cell )</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>